Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy

Inclusion Criteria: * Any patient with a documented malignancy initiating treatment including (as a single agent or in combination with other drugs) any one of the following cancer therapeutics: o Fluorouracil (5FU), capecitabine, irinotecan, paclitaxel, docetaxel, cabazitaxel, crizotinib, sorafenib, sunitinib, erlotinib, or lapatinib * Any pathologically confirmed malignancy for which the patient would receive any of the listed cancer therapeutics * Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 * Patient must have an estimated life expectancy of at least 6 months * Absolute neutrophil count (ANC) \> 1500 * Platelets \> 100K * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 2.5 x ULN (upper limit normal) * Serum bilirubin \< 1.5 x ULN * Serum creatinine \< 1.5 x ULN * Ability to understand and the willingness to sign a written informed consent document and comply with the treatment protocol Exclusion Criteria: * Patients currently undergoing treatment with the above listed therapeutics at time of initiation of trial; patients can have had prior treatment(s) with one or more of the agents if they are initiating a new treatment with another agent on the list, provided they have had at least a 2 week "washout" period * Patients currently taking anti-diarrheal medications or therapy * Patients undergoing hemodialysis * Patients with known allergic or hypersensitivity reaction to probiotics, yoghurt, or similar diet or supplemental products * Acute or chronic diarrhea, including lactose intolerance, gluten or other dietary sensitivity resulting in gastrointestinal symptoms * Pregnant or nursing patients * Known human immunodeficiency virus (HIV) positive * Prior abdominal surgery resulting in a stoma, ostomy, fistula, or other anatomic defect * Concurrent or near future radiotherapy; prior, completed radiotherapy allowed; any radiotherapy within the vicinity of the GI tract must have been completed at least 4 weeks prior to start of trial * Treatment with any investigational drug within 4 weeks prior to enrollment * Current treatment with antibiotics or other gut motility agents within 2 weeks of starting study medication * Abnormal thyroid function that is not controlled with medication * Patients taking other dietary supplements within 2 weeks of starting study medication * Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial